



Attorney's Docket No. 1543.004 (5784-81)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

1653

p#13

Re: Whitehouse
Appl. No.: 09/385,114
Filed: August 27, 1999
For: ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2
AND METHOD OF USE

Group Art Unit: 1653
Examiner: H. Robinson

RECEIVED

APR 19 2001

TECH CENTER 1600/2900

April 13, 2001

Commissioner for Patents
Washington, DC 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)**

Sir:

Attached is a list of documents on form PTO-1449 together with copies of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

A check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 16-0605.

Respectfully submitted,

04/18/2001 ETULU1 00000075 09385114

01 FC:126

180.00 OP

Leslie T. Henry
Registration No. 45,714

CUSTOMER NO. 000826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000

Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on April 13, 2001.

Polly P. Burton